Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Comment by losingmyshirton Mar 09, 2021 10:16am
108 Views
Post# 32751751

RE:Hey, the New Guy, the Doc, another good move SAB ummmmmm

RE:Hey, the New Guy, the Doc, another good move SAB ummmmmm

Inhibition of Experimental Gingivitis in Beagle Dogs With Topical Mercaptoalkylguanidines

  • Autores: Steven OffenbacherCsaba SzabDavid W. PaquetteAdam RosenbergZsolt LohinaiGarry J. Southan, Ray C. Williams
  • Localizacin: Journal of periodontologyISSN 0022-3492, Vol. 77, Nº. 3, 2006pgs. 385-391
  • Idioma: ingls
  • Texto completo no disponible (Saber ms ...)
  • Resumen
    • Inhibition of Experimental Gingivitis in Beagle Dogs With Topical Mercaptoalkylguanidines David W. Paquette,* Adam Rosenberg,* Zsolt Lohinai,† Garry J. Southan,‡ Ray C. Williams,* Steven Offenbacher,* and Csaba Szab†‡ *Department of Periodontology, School of Dentistry, Comprehensive Center for Inflammatory Disorders, University of North Carolina, Chapel Hill, NC.

      †Department of Human Physiology and Clinical Experimental Research, Semmelweis University Medical School, Budapest, Hungary.

      ‡Inotek Pharmaceuticals, Beverly, MA.

      Correspondence: Dr. David W. Paquette, Department of Periodontology, School of Dentistry, Comprehensive Center for Inflammatory Disorders, University of North Carolina, Brauer Hall, CB 7450, Chapel Hill, NC 27599-7450. E-mail: david_paquette@dentistry.unc.edu.

      Background: Nitric oxide is a free radical produced in host tissues by constitutive and inducible forms of the enzyme nitric oxide synthase. Nitric oxide plays physiological roles, but it is also involved in the pathophysiology of several inflammatory conditions, including arthritis, ulcerative colitis, and circulatory shock. Local increases in inducible nitric oxide synthase (iNOS) and reactive nitrogen products have also been demonstrated in humans and animals with periodontal disease. This masked, randomized, placebo-controlled preclinical investigation examined the effect of two mercaptoalkylguanidines, mercaptoethylguanidine (MEG) and guanidinoethyldisulfide (GED), which are iNOS inhibitors and reactive nitrogen scavenging compounds, on the development of experimental gingivitis in beagle dogs.

      Methods: Fifteen female, 1-year-old beagles first completed a 2-week dose-escalation experiment during which a maximum tolerated dose was determined for MEG and GED gels. Thereafter, all animals were brought to optimal gingival health by mechanical scaling, followed by rigorous daily toothbrushing over a 4-week washout period. Experimental gingivitis was then induced, with cessation of plaque control and institution of a soft diet over 8 weeks. Beagles randomly received 0.3% MEG, 0.3% GED, or placebo (vehicle) gels, topically applied twice daily to premolar teeth. Gingival inflammation, bleeding tendency, and supragingival plaque were clinically measured at baseline and at 2, 3, 4, 6, and 8 weeks. Comparisons among groups and between group pairs (active versus placebo) were made using Kruskal-Wallis tests.

<< Previous
Bullboard Posts
Next >>